As of 2025-06-02, the Intrinsic Value of Thalys Medical Technology Group Inc (603716.SS) is 1.92 CNY. This 603716.SS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 12.54 CNY, the upside of Thalys Medical Technology Group Inc is -84.70%.
The range of the Intrinsic Value is 0.51 - 5.70 CNY
Based on its market price of 12.54 CNY and our intrinsic valuation, Thalys Medical Technology Group Inc (603716.SS) is overvalued by 84.70%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 0.51 - 5.70 | 1.92 | -84.7% |
| DCF (Growth 10y) | 3.33 - 13.08 | 5.99 | -52.3% |
| DCF (EBITDA 5y) | 9.71 - 14.78 | 12.26 | -2.3% |
| DCF (EBITDA 10y) | 11.74 - 19.96 | 15.61 | 24.5% |
| Fair Value | -5.93 - -5.93 | -5.93 | -147.32% |
| P/E | (29.34) - (29.60) | (30.98) | -347.0% |
| EV/EBITDA | (12.05) - (0.43) | (7.22) | -157.6% |
| EPV | (6.30) - (7.29) | (6.79) | -154.2% |
| DDM - Stable | (7.53) - (23.25) | (15.39) | -222.7% |
| DDM - Multi | 1.82 - 4.63 | 2.64 | -78.9% |
| Market Cap (mil) | 2,395.39 |
| Beta | 1.36 |
| Outstanding shares (mil) | 191.02 |
| Enterprise Value (mil) | 3,116.49 |
| Market risk premium | 6.13% |
| Cost of Equity | 11.82% |
| Cost of Debt | 5.00% |
| WACC | 9.57% |